Hjem
Håkon Reikvams bilde

Håkon Reikvam

Professor
  • E-postHakon.Reikvam@uib.no
  • Telefon+47 55 58 54 08
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2022). Weight gain during treatment course of allogenic hematopoietic stem cell transplantation in patients with hematological malignancies affects treatment outcome. Cytotherapy. 1190-1194.
  • Vis forfatter(e) (2022). Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients. Cancers. 21 sider.
  • Vis forfatter(e) (2022). Patients with Bacterial Sepsis Are Heterogeneous with Regard to Their Systemic Lipidomic Profiles. Metabolites. 21 sider.
  • Vis forfatter(e) (2022). Når blodet flyter langsomt. Tidsskrift for Den norske legeforening.
  • Vis forfatter(e) (2022). NPM1-mutated patient-derived AML cells are more vulnerable to rac1 inhibition. Biomedicines. 16 sider.
  • Vis forfatter(e) (2022). Musculoskeletal Chronic Graft versus Host Disease-A Rare Complication to Allogeneic Hematopoietic Stem Cell Transplant: A Case-Based Report and Review of the Literature. Current Oncology. 8415-8430.
  • Vis forfatter(e) (2022). MicroRNA serum profiles and chronic graft-versus-host disease. Blood Advances. 5295-5306.
  • Vis forfatter(e) (2022). Leukemia cutis. Tidsskrift for Den norske legeforening.
  • Vis forfatter(e) (2022). Heterogeneity of patient-derived acute myeloid leukemia cells subjected to SYK in vitro inhibition. International Journal of Molecular Sciences. 21 sider.
  • Vis forfatter(e) (2022). Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms. Scandinavian Journal of Clinical and Laboratory Investigation.
  • Vis forfatter(e) (2022). Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules.
  • Vis forfatter(e) (2022). Eksamensformer i de norske medisinstudiene. Tidsskrift for Den norske legeforening. 1-11.
  • Vis forfatter(e) (2022). Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis. Current Oncology. 2193-2198.
  • Vis forfatter(e) (2022). An Abrupt Transition to Digital Teaching—Norwegian Medical Students and Their Experiences of Learning Output during the Initial Phase of the COVID-19 Lockdown. Healthcare.
  • Vis forfatter(e) (2021). p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. Cells. 14 sider.
  • Vis forfatter(e) (2021). Thrombosis and thrombocytopenia after HPV vaccination. Journal of Thrombosis and Haemostasis.
  • Vis forfatter(e) (2021). Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis. Case Reports in Critical Care.
  • Vis forfatter(e) (2021). Proteomic studies of primary acute myeloid leukemia cells derived from patients before and during disease-stabilizing treatment based on all-trans retinoic acid and valproic acid. Cancers.
  • Vis forfatter(e) (2021). Proteomic Characterization of Spontaneous Stress-Induced In Vitro Apoptosis of Human Acute Myeloid Leukemia Cells; Focus on Patient Heterogeneity and Endoplasmic Reticulum Stress. Hemato. 607-627.
  • Vis forfatter(e) (2021). Platelet microparticles protect acute myelogenous leukemia cells against daunorubicin-induced apoptosis. Cancers. 1-17.
  • Vis forfatter(e) (2021). Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells. Diseases.
  • Vis forfatter(e) (2021). Hfe genotype, ferritin levels and transferrin saturation in patients with suspected hereditary hemochromatosis. Genes. 11 sider.
  • Vis forfatter(e) (2021). Effects of the autophagy‐inhibiting agent chloroquine on acute myeloid leukemia cells; characterization of patient heterogeneity. Journal of Personalized Medicine. 1-23.
  • Vis forfatter(e) (2020). Targeting cellular metabolism in acute myeloid leukemia and the role of patient heterogeneity. Cells. 1-26.
  • Vis forfatter(e) (2020). Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation. Transplantology. 102-110.
  • Vis forfatter(e) (2020). Inhibition of NF-κB signaling alters acute myelogenous leukemia cell transcriptomics. Cells. 1-19.
  • Vis forfatter(e) (2020). Hyperferritinemi-katarakt-syndrom. Tidsskrift for Den norske legeforening.
  • Vis forfatter(e) (2020). Hemophagocytic lymphohistiocytosis and miliary tuberculosis in a previously healthy individual: a case report. Journal of Medical Case Reports. 1-9.
  • Vis forfatter(e) (2020). Critical upper airway obstruction as the first symptom of acute myeloid leukemia - an anesthesiologic reminder. Clinics and Practice.
  • Vis forfatter(e) (2020). A Patient With Maculopapular Rash and Lichenoid Skin Damage Caused by Ponatinib. Journal of International Medical Research.
  • Vis forfatter(e) (2019). High constitutive cytokine release by primary human acute myeloid leukemia cells is associated with a specific intercellular communication phenotype. Journal of Clinical Medicine.
  • Vis forfatter(e) (2019). En mann i 70-årene med ryggsmerter, mageplager og utslett. Tidsskrift for Den norske legeforening. 7 sider.
  • Vis forfatter(e) (2019). Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy.
  • Vis forfatter(e) (2019). Dasatinib is an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Expert Opinion on Investigational Drugs.
  • Vis forfatter(e) (2019). Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Expert Opinion on Investigational Drugs. 411-420.
  • Vis forfatter(e) (2019). Behandling av akutt myelogen leukemi hos eldre. Tidsskrift for Den norske legeforening. 1-6.
  • Vis forfatter(e) (2018). Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
  • Vis forfatter(e) (2018). The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis. Cytotherapy. 740-754.
  • Vis forfatter(e) (2018). Successful eradication of leptomeningeal plasma cell disease. Oxford Medical Case Reports. 193-197.
  • Vis forfatter(e) (2018). Resistance to the antiproliferative in vitro effect of PI3K-Akt-mTOR inhibition in primary human acute myeloid leukemia cells is associated with altered cell metabolism. International Journal of Molecular Sciences. 1-18.
  • Vis forfatter(e) (2018). Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. Biomarker Research.
  • Vis forfatter(e) (2018). Patients with treatment-requiring chronic graft versus host disease after allogeneic stem cell transplantation have altered metabolic profiles due to the disease and immunosuppressive therapy: Potential implication for biomarkers. Frontiers in Immunology. 1-15.
  • Vis forfatter(e) (2018). Inflammatory mediator profiles differ in sepsis patients with and without bacteremia. Frontiers in Immunology. 1-12.
  • Vis forfatter(e) (2018). Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. Vox Sanguinis. 657-668.
  • Vis forfatter(e) (2018). Clonal heterogeneity reflected by pi3k-akt-mtor signaling in human acute myeloid leukemia cells and its association with adverse prognosis. Cancers. 1-15.
  • Vis forfatter(e) (2018). Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. Case reports in hematology.
  • Vis forfatter(e) (2017). Ringsideroblaster. Tidsskrift for Den norske legeforening.
  • Vis forfatter(e) (2017). Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism. Expert opinion on therapeutic targets. 357-369.
  • Vis forfatter(e) (2017). Non-curative surgery for aortoenteric fistula. Journal of Surgical Case Reports (JSCR).
  • Vis forfatter(e) (2017). Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 1-13.
  • Vis forfatter(e) (2017). CDC25 inhibition in acute myeloid leukemia - A study of patient heterogeneity and the effects of different inhibitors. Molecules. 1-18.
  • Vis forfatter(e) (2017). Altered immune activation and IL-23 signaling in response to Candida albicans in autoimmune polyendocrine syndrome type 1. Frontiers in Immunology. 1-10.
  • Vis forfatter(e) (2017). A prospective observational study on effects of fever on red cell transfusion outcome. Vox Sanguinis. 484-486.
  • Vis forfatter(e) (2016). The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation. Metabolomics.
  • Vis forfatter(e) (2016). Pretransplant levels of CRP and interleukin-6 family cytokines; effects on outcome after allogeneic stem cell transplantation. International Journal of Molecular Sciences.
  • Vis forfatter(e) (2016). Nutrition in allogeneic stem cell transplantion - Clinical guidelines and immunobiological aspects. Current Pharmaceutical Biotechnology. 92-104.
  • Vis forfatter(e) (2016). Myeloproliferative neoplasiar og JAK2-mutasjonar :. Tidsskrift for Den norske legeforening. 1889-1894.
  • Vis forfatter(e) (2016). Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 1-14.
  • Vis forfatter(e) (2016). A subset of patients with acute myeloid leukemia has leukemia cells characterized by chemokine responsiveness and altered expression of transcriptional as well as angiogenic regulators. Frontiers in Immunology.
  • Vis forfatter(e) (2015). The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers - a comparative study of serum versus plasma samples. JIM - Journal of Immunological Methods. 19-28.
  • Vis forfatter(e) (2015). The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. Stem Cell Research. 530-541.
  • Vis forfatter(e) (2015). Plasmaceller med inklusjonar. Tidsskrift for Den norske legeforening.
  • Vis forfatter(e) (2015). Metabolic serum profiles for patients receiving allogeneic stem cell transplantation: the pretransplant profile differs for patients with and without posttransplant capillary leak syndrome. Disease Markers. 13 sider.
  • Vis forfatter(e) (2015). Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. OncoTarget. 2794-2811.
  • Vis forfatter(e) (2015). Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. BMC Pharmacology & Toxicology.
  • Vis forfatter(e) (2015). Connexin expression in human acute myeloid leukemia cells: Identification of patient subsets based on protein and global gene expression profiles. International Journal of Molecular Medicine. 645-652.
  • Vis forfatter(e) (2015). Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis. Thrombosis Research. 30-39.
  • Vis forfatter(e) (2014). Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis. SpringerPlus. 1-9.
  • Vis forfatter(e) (2014). Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation. Journal of transplantation. 1-9.
  • Vis forfatter(e) (2014). Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer.
  • Vis forfatter(e) (2014). Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells. Expert opinion on therapeutic targets. 1237-1251.
  • Vis forfatter(e) (2014). Comparison of in vitro responses to fresh whole blood and reconstituted whole blood after collagen stimulation. Blood Transfusion. 50-55.
  • Vis forfatter(e) (2014). Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients . Transfusion and Apheresis Science. 97-102.
  • Vis forfatter(e) (2014). Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. British Journal of Haematology. 200-211.
  • Vis forfatter(e) (2013). Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Current Cancer Drug Targets. 30-47.
  • Vis forfatter(e) (2013). Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma. Cytotherapy. 850-860.
  • Vis forfatter(e) (2013). Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells. OncoTarget. 830-843.
  • Vis forfatter(e) (2013). Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opinion on Investigational Drugs. 551-563.
  • Vis forfatter(e) (2013). Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfusion Medicine. 397-406.
  • Vis forfatter(e) (2013). Forskningsveiledning - en av de essensielle faktorene på «veien til doktorgrad». UNIPED. 45-54.
  • Vis forfatter(e) (2013). Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacology & Toxicology. 13 sider.
  • Vis forfatter(e) (2013). Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients. Cell Proliferation. 554-562.
  • Vis forfatter(e) (2012). The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications. Biology of Blood and Marrow Transplantation. 190-199.
  • Vis forfatter(e) (2012). The effects of selective serotonin reuptake inhibitors on platelet function in whole blood and platelet concentrates. Platelets. 299-308.
  • Vis forfatter(e) (2012). Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. European Journal of Haematology. 478-490.
  • Vis forfatter(e) (2012). Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress. Bone Marrow Research.
  • Vis forfatter(e) (2012). Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology. 468-480.
  • Vis forfatter(e) (2012). Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. American Journal of Hematology. 368-376.
  • Vis forfatter(e) (2011). Evaluation of noninvasive methods for the estimation of haemoglobin content in red blood cell concentrates. Transfusion Medicine. 145-149.
  • Vis forfatter(e) (2011). A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. European Cytokine Network. 52-62.
  • Vis forfatter(e) (2010). The Mirasol (R) Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. Blood Transfusion. 186-192.
  • Vis forfatter(e) (2010). Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opinion on Investigational Drugs. 169-183.
  • Vis forfatter(e) (2010). Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. European Journal of Haematology. 239-251.
  • Vis forfatter(e) (2010). A pilot study of the possibility and the feasibility of haemoglobin dosing with red blood cells transfusion. Vox Sanguinis. 71-76.
  • Vis forfatter(e) (2009). Thrombelastography. Transfusion and Apheresis Science. 119-123.
  • Vis forfatter(e) (2009). Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors; release profile and pharmacological modulaion. European Journal of Haematology. 239-251.
  • Vis forfatter(e) (2009). Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. Critical reviews in oncogenesis. 1-41.
Leder
  • Vis forfatter(e) (2022). Pure red cell aplasia after hematopoietic stem cell transplantation - experimental therapeutic approaches. Expert Opinion on Investigational Drugs. 881-884.
  • Vis forfatter(e) (2022). Proteomic approaches for untangling pharmacological targets in acute myelogenous leukemia. Expert Review of Proteomics. 73-76.
  • Vis forfatter(e) (2022). Cytomegalovirus induced hemophagocytic lymphohistiocytosis: diagnostic and treatment challenges for the future. Expert Review of Hematology. 667-670.
  • Vis forfatter(e) (2022). Autologous hematopoietic stem cell grafts - moving away from a one-size-fits-all approach. Expert Review of Hematology. 1-4.
  • Vis forfatter(e) (2021). Future perspective: precision medicine to improve treatment results in the settings of allogenic stem cell transplantation for acute myelogenous leukemia. Expert Review of Precision Medicine and Drug Development. 151-155.
  • Vis forfatter(e) (2020). Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach. Expert Review of Anticancer Therapy. 1-5.
  • Vis forfatter(e) (2013). Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneity. Expert Opinion on Investigational Drugs. 1365-1370.
  • Vis forfatter(e) (2011). Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia-Targeting of disease heterogeneity through direct and indirect antileukemic effects. Leukemia Research. 1156-1158.
  • Vis forfatter(e) (2010). Therapeutic targeting of NF-kappa B in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity. Expert opinion on therapeutic targets. 1139-1142.
  • Vis forfatter(e) (2010). Heat shock protein 90 (HSP90) inhibition-From experimental to clinical studies. Leukemia Research. 1422-1423.
  • Vis forfatter(e) (2009). Does the preoperative iron status predict transfusion requirement of orthopedic patients? Transfusion and Apheresis Science. 213-217.
Leserinnlegg
  • Vis forfatter(e) (2012). The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status. Leukemia. 557-559.
Short communication
  • Vis forfatter(e) (2019). Mondor's disease after extensive training with Nordic walking. Oxford Medical Case Reports. 356-358.
Populærvitenskapelig artikkel
  • Vis forfatter(e) (2021). En ung kvinne med pustevansker og proteinuri. Tidsskrift for Den norske legeforening.
Brev til redaktøren
  • Vis forfatter(e) (2022). Human papilloma virus vaccine and VITT antibody induction. American Journal of Hematology. E363-E364.
Doktorgradsavhandling
  • Vis forfatter(e) (2017). Cytokine profiles in inflammation .
  • Vis forfatter(e) (2012). New therapeutic targets in human acute myeloid leukemia.
Sammendrag/abstract
  • Vis forfatter(e) (2010). Why is potentional blood donors deferred from donation? Haematologica. 738-738.
  • Vis forfatter(e) (2010). PHARMACOLOGICAL TARGETING OF THE PI3K-AKT/PKB-MTOR PATHWAY ALTERS LOCAL ANGIOREGULATION IN ACUTE MYELOGENOUS LEUKEMIA. Haematologica. 266-266.
  • Vis forfatter(e) (2009). TREATMENT OF ORBISAC DERIVED BUFFY COAT PLATELETS WITH THE MIRASOL (R) PATHOGEN REDUCTION TECHNOLOGY AND STORAGE IN ADDITIVE SOLUTION. Haematologica. 284-284.
  • Vis forfatter(e) (2009). PRIMARY HUMAN ACUTE MYELOGENOUS LEUKEMIA CELLS SHOW CONSTITUTIVE RELEASE OF SEVERAL MATRIX METALLOPROTEASES AND THEIR INHIBITORS. Haematologica. 545-545.
Poster
  • Vis forfatter(e) (2022). FLT3L and GM-CSF improve conventional dendritic cell viability and function.
  • Vis forfatter(e) (2014). The Role of Research Supervision on Doctoral Degree.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2022). Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia. Molecules.
  • Vis forfatter(e) (2022). Hematopoiesis, Inflammation and Aging—The Biological Background and Clinical Impact of Anemia and Increased C‐Reactive Protein Levels on Elderly Individuals. Journal of Clinical Medicine.
  • Vis forfatter(e) (2022). Concomitant Hemophagocytic Lymphohistiocytosis and Cytomegalovirus Disease: A Case Based Systemic Review. Frontiers in medicine. 1-14.
  • Vis forfatter(e) (2021). Thrombocytopaenia in the critically ill. Tidsskrift for Den norske legeforening. 7 sider.
  • Vis forfatter(e) (2021). Therapeutic use of valproic acid and all-trans retinoic acid in acute myeloid leukemia—literature review and discussion of possible use in relapse after allogeneic stem cell transplantation. Pharmaceuticals.
  • Vis forfatter(e) (2021). Immunoglobulin-storing histiocytosis: A case based systemic review. Journal of Clinical Medicine. 21 sider.
  • Vis forfatter(e) (2021). Hyperferritinemia—a clinical overview. Journal of Clinical Medicine.
  • Vis forfatter(e) (2021). Cytokine release syndrome in the immunotherapy of hematological malignancies: The biology behind and possible clinical consequences. Journal of Clinical Medicine.
  • Vis forfatter(e) (2021). Carbapenem‐resistant enterobacteriaceae—implications for treating acute leukemias, a subgroup of hematological malignancies. Antibiotics. 1-16.
  • Vis forfatter(e) (2020). The PI3K-AKT-MTOR signaling pathway in human acute myeloid leukemia (AML) cells. International Journal of Molecular Sciences. 1-22.
  • Vis forfatter(e) (2020). GRAFT MOT VERT SJUKDOM. Indremedisineren.
  • Vis forfatter(e) (2020). Febrile neutropenia in acute leukemia. Epidemiology, etiology, pathophysiology and treatment. Mediterranean Journal of Hematology and Infectious Diseases (MJHID). 1-19.
  • Vis forfatter(e) (2020). COVID-19 and venous thromboembolism - prophylaxis and treatment. Tidsskrift for Den norske legeforening. 6 sider.
  • Vis forfatter(e) (2019). Trisomy 8 in acute myeloid leukemia. Expert Review of Hematology. 947-958.
  • Vis forfatter(e) (2019). Precision medicine for TP53-mutated acute myeloid leukemia. Expert Review of Precision Medicine and Drug Development. 263-274.
  • Vis forfatter(e) (2018). The possible importance of β3 integrins for leukemogenesis and chemoresistance in acute myeloid leukemia. International Journal of Molecular Sciences. 1-17.
  • Vis forfatter(e) (2018). Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia. Expert Opinion on Investigational Drugs. 377-387.
  • Vis forfatter(e) (2018). Cytokines, adhesion molecules, and matrix metalloproteases as predisposing, diagnostic, and prognostic factors in venous thrombosis. Frontiers in medicine. 1-11.
  • Vis forfatter(e) (2017). Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. Expert Opinion on Drug Discovery. 1053-1065.
  • Vis forfatter(e) (2017). Microcirculation and red cell transfusion in patients with sepsis. Transfusion and Apheresis Science. 900-905.
  • Vis forfatter(e) (2017). Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment. Expert Review of Clinical Immunology. 553-569.
  • Vis forfatter(e) (2015). STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia. Expert Review of Hematology. 29-41.
  • Vis forfatter(e) (2015). Emerging therapeutic targets in human acute myeloid leukemia (part 2) – bromodomain inhibition should be considered as a possible strategy for various patient subsets. Expert Review of Hematology. 315-327.
  • Vis forfatter(e) (2015). Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication. Expert Review of Hematology. 299-313.
  • Vis forfatter(e) (2014). Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid Leukemia - The possibility to target several kinases through inhibition of the various CDC25 isoforms. Molecules. 18414-18447.
  • Vis forfatter(e) (2014). Heat shock protein 90 – a potential target in the treatment of human acute myelogenous leukemia. Advances in cancer drug targets. 3-53.
  • Vis forfatter(e) (2014). Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia? Expert opinion on therapeutic targets. 929-944.
  • Vis forfatter(e) (2014). Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: Immunological mechanisms and the results from clinical studies. Cancer Immunology and Immunotherapy. 757-777.
  • Vis forfatter(e) (2014). Akutt promyelocyttleukemi. Tidsskrift for Den norske legeforening. 1052-1055.
  • Vis forfatter(e) (2013). The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine-the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. Toxins. 336-362.
  • Vis forfatter(e) (2012). Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia. 563-571.
  • Vis forfatter(e) (2012). The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. European Cytokine Network. 140-153.
  • Vis forfatter(e) (2012). Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia? Expert Opinion on Investigational Drugs. 587-603.
  • Vis forfatter(e) (2012). High-dose etoposide in allogeneic stem cell transplantation. Cancer Chemotherapy and Pharmacology. 765-782.
  • Vis forfatter(e) (2011). Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukemia. Journal of Proteomics. 269-281.
  • Vis forfatter(e) (2011). Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies. Bone Marrow Research.
  • Vis forfatter(e) (2011). Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. Journal of Biomedicine and Biotechnology. 23 sider.
  • Vis forfatter(e) (2010). The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia. Current Medicinal Chemistry. 4448-4461.
  • Vis forfatter(e) (2010). The Chemokine Network in Acute Myelogenous Leukemia: Molecular Mechanisms Involved in Leukemogenesis and Therapeutic Implications. Current Topics in Microbiology and Immunology. 149-172.
  • Vis forfatter(e) (2010). Clinical proteomics of myeloid leukemia. Genome Medicine.
  • Vis forfatter(e) (2009). Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opinion on Investigational Drugs. 433-455.
  • Vis forfatter(e) (2009). Heat shock protein 90-a potential target in the treatment of human acute myelogenous leukemia. Current Cancer Drug Targets. 761-776.
  • Vis forfatter(e) (2009). Granulocyttransfusjon. Tidsskrift for Den norske legeforening. 416-419.
Fagartikkel
  • Vis forfatter(e) (2020). Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy. Case Reports in Anesthesiology. 5 sider.
  • Vis forfatter(e) (2019). En kvinne i 40-?rene med bekkensmerter og uklare MR-funn. Tidsskrift for Den norske legeforening. 7 sider.
  • Vis forfatter(e) (2019). Behandling av akutt myelogen leukemi hos eldre. Tidsskrift for Den norske legeforening.
  • Vis forfatter(e) (2017). Ei ung kvinne med brystsmerter og dyspne. Tidsskrift for Den norske legeforening. 8 sider.
  • Vis forfatter(e) (2012). En mann med smerter etter kneoperasjon. Tidsskrift for Den norske legeforening. 1472-1474.

Se fullstendig oversikt over publikasjoner i CRIStin.